Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)
- Conditions
- Unresectable Stage III or IV Malignant Melanoma
- Interventions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT00261365
- Locations
- 🇺🇸
Comprehensive Cancer Center, Palm Springs, California, United States
🇺🇸The Angeles Clinic And Research Institution, Santa Monica, California, United States
🇸🇪Local Institution, Stockholm, Sweden
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
- Conditions
- Stage III Prostate CancerProstate AdenocarcinomaStage IV Prostate CancerProstate CarcinomaRecurrent Prostate Carcinoma
- Interventions
- Drug: BicalutamideDrug: FlutamideDrug: Goserelin AcetateDrug: IpilimumabDrug: Leuprolide AcetateOther: Pharmacological Study
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 112
- Registration Number
- NCT00170157
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 248
- Registration Number
- NCT00162123
- Locations
- 🇺🇸
The Angeles Clinic & Research Inst., Los Angeles, California, United States
🇺🇸University Of Chicago, Chicago, Illinois, United States
🇺🇸Indiana Oncology Hematology Consultants, Indianapolis, Indiana, United States
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChildhood Myelodysplastic SyndromesChronic Myelogenous Leukemia, BCR-ABL1 PositiveDisseminated NeuroblastomaMalignant Neoplasm
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-03-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00060372
- Locations
- 🇺🇸
Scripps Clinic - La Jolla, La Jolla, California, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.